Rapid Micro Biosystems

Rapid Micro Biosystems, Inc. is an innovative life sciences technology company. It provides mission critical automation solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus in 2006 and is headquartered in Lowell, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rapid Micro Biosystems surpasses Q1 revenue targets, eyes global expansion

Rapid Micro Biosystems delivered a strong Q1 performance, exceeding revenue guidance and setting new records in consumable sales.
The company's focus on product innovation and customer-centric solutions positions it well for sustained growth and market expansion.
While challenges in revenue targets and margin improvements exist, strategic planning and operational enhancements offer opportunities for future success.

Rapid Micro Biosystems reports strong Q2 growth and cost-saving initiatives

Rapid Micro Biosystems showcased robust revenue growth and margin improvement in Q2 2024, driven by successful customer engagement and product placements.
While challenges like net losses persist, the company's proactive cost management and revenue outlook reaffirmation signal a commitment to financial health.
Opportunities lie in achieving positive cash flow by 2027, sustained revenue growth, and operational efficiency enhancements for long-term success.

Rapid Micro Biosystems achieves record revenue and focuses on growth

Rapid Micro Biosystems reported strong Q3 performance with record revenue and improved gross margins.
The company's commercial strategy and product launches are driving customer engagement and sales growth.
While challenges like achieving positive cash flow exist, opportunities for revenue growth through new modalities are promising.
Strategic planning and operational efficiency will be key in navigating market dynamics and sustaining growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapid Micro Biosystems, Inc. is a life sciences technology company. It provides automated solutions to facilitate the efficient manufacturing and safe release of healthcare products such as biologics, vaccines, cell & gene therapies, and sterile injectable. The company was founded by Donald Straus on December 29, 2006 and is headquartered in Lexington, MA.

Reports third quarter 2021 total revenue of $6.9 million and commercial revenue of $6.3 million

Rapid Micro Biosystems Reports Third Quarter 2021 Financial Results

LOWELL, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will be participating in the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021.

Rapid Micro Biosystems to Present at Stifel 2021 Virtual Healthcare Conference

Conference Call to Discuss Results on November 12, 2021 at 5:00am Pacific Time/8:00am Eastern Time Conference Call to Discuss Results on November 12, 2021 at 5:00am Pacific Time/8:00am Eastern Time

Rapid Micro to Announce Third Quarter 2021 Financial Results on November 11, 2021

LOWELL, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (Rapid Micro), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of veteran life sciences executive Andy Keys to the newly created position of Chief Commercial Officer (CCO).

Rapid Micro Biosystems Announces Appointment of Andy Keys as Chief Commercial Officer

LOWELL, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to accelerate the detection of microbial contamination in the manufacture of pharmaceuticals, biologics, medical devices, and personal care products, is excited to announce its participation as an exhibitor and presenter of two scientific posters at the 2021 Parenteral Drug Association (PDA) Pharmaceutical Microbiology Conference.

Rapid Micro Biosystems to Exhibit at the 2021 PDA Pharmaceutical Microbiology Conference on October 4-6

Reports second quarter 2021 commercial revenue of $5.7 million, representing 135% year-over-year growth

Rapid Micro Biosystems Reports Second Quarter 2021 Financial Results and Provides Business Update and Full Year 2021 Outlook

LOWELL, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will release financial results for the second quarter of 2021 after market close on Thursday, August 26, 2021.

Rapid Micro Biosystems to Announce Second Quarter 2021 Financial Results on August 26, 2021

LOWELL, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the underwriters of its previously announced initial public offering of Class A common stock have exercised their option to purchase additional shares in part for 1,086,604 shares at the public offering price of $20.00 per share less underwriting discounts and commissions, for additional gross proceeds to Rapid Micro of $21.7 million. The exercise of the over-allotment option closed on August 4, 2021.

Rapid Micro Biosystems Announces Exercise and Closing of Over-Allotment Option in Initial Public Offering

LOWELL, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Melinda Litherland to its board of directors.

Rapid Micro Biosystems Announces Appointment of Melinda Litherland to Board of Directors

LOWELL, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the pricing of its initial public offering of 7,920,000 shares of its Class A common stock at a price to the public of $20.00 per share. All of the shares of Class A common stock are being offered by Rapid Micro. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Rapid Micro, are expected to be $158.4 million, excluding any exercise of the underwriters' option to purchase additional shares. Rapid Micro's Class A common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “RPID” on July 15, 2021. The offering is expected to close on July 19, 2021, subject to satisfaction of customary closing conditions. In addition, Rapid Micro has granted the underwriters a 30-day option to purchase up to an additional 1,188,000 shares of Rapid Micro's Class A common stock at the initial public offering price less the underwriting discounts and commissions.

Rapid Micro Biosystems Announces Pricing of Initial Public Offering

Rapid Micro Biosystems has filed proposed terms for a $125.4 million IPO. The firm sells microbial quality control systems to pharmaceutical manufacturing firms worldwide.

Rapid Micro Biosystems Prepares $125 Million IPO

News for Rapid Micro Biosystems Stock (RPID)